From symptoms to strategy: pre-procedural NYHA-class as a key to risk stratification and personalized TAVR-management.

Front Cardiovasc Med · 2026 · PMC13133034 · PMID 42079705

Europe PMC DOI

hedged sentence

0.1750

closest p · 3.5× alpha

0.1750

boldest claim

The sentences

did not reach statistical significancep = 0.175not close (p > 0.1)

In this model, NYHA class IV was associated with increased 30-day mortality (OR 4.76, 95% CI 2.05–11.07, p < 0.001), whereas NYHA class III did not reach statistical significance (OR 1.71, 95% CI 0.79–3.73, p = 0.175).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.